However, the therapeutic utility of restoring BRM and BRG1 expression via HDAC inhibition is still in question as in vitro work has demonstrated that while reexpression of these proteins does slow cancer cell growth, it also promotes metastatic traits [63]. This evidence concerns the gene SMARCA4 and cancer.